High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data.


Journal

World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448

Informations de publication

Date de publication:
28 Dec 2020
Historique:
received: 21 10 2020
revised: 26 11 2020
accepted: 06 12 2020
entrez: 28 1 2021
pubmed: 29 1 2021
medline: 3 2 2021
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) disease can frequently affect the liver. Data on hepatic histopathological findings in COVID-19 is scarce. To characterize hepatic pathological findings in patients with COVID-19. We conducted a systematic review with meta-analysis registered on PROSPERO (CRD42020192813), following PRISMA guidelines. Eligible trials were those including patients of any age and COVID-19 diagnosis based on a molecular test. Histopathological reports from deceased COVID-19 patients undergoing autopsy or liver biopsy were reviewed. Articles including less than ten patients were excluded. Proportions were pooled using random-effects models. We identified 18 studies from 7 countries; all were case reports and case series from autopsies. All the patients were over 15 years old, and 67.2% were male. We performed a meta-analysis of 5 studies, including 116 patients. Pooled prevalence estimates of liver histopathological findings were hepatic steatosis 55.1% [95% confidence interval (CI): 46.2-63.8], congestion of hepatic sinuses 34.7% (95%CI: 7.9-68.4), vascular thrombosis 29.4% (95%CI: 0.4-87.2), fibrosis 20.5% (95%CI: 0.6-57.9), Kupffer cell hyperplasia 13.5% (95%CI: 0.6-54.3), portal inflammation 13.2% (95%CI: 0.1-48.8), and lobular inflammation 11.6% (95%CI: 0.3-35.7). We also identified the presence of venous outflow obstruction, phlebosclerosis of the portal vein, herniated portal vein, periportal abnormal vessels, hemophagocytosis, and necrosis. We found a high prevalence of hepatic steatosis and vascular thrombosis as major histological liver features. Other frequent findings included portal and lobular inflammation and Kupffer cell hyperplasia or proliferation. Further studies are needed to establish the mechanisms and implications of these findings.

Sections du résumé

BACKGROUND BACKGROUND
Coronavirus disease 2019 (COVID-19) disease can frequently affect the liver. Data on hepatic histopathological findings in COVID-19 is scarce.
AIM OBJECTIVE
To characterize hepatic pathological findings in patients with COVID-19.
METHODS METHODS
We conducted a systematic review with meta-analysis registered on PROSPERO (CRD42020192813), following PRISMA guidelines. Eligible trials were those including patients of any age and COVID-19 diagnosis based on a molecular test. Histopathological reports from deceased COVID-19 patients undergoing autopsy or liver biopsy were reviewed. Articles including less than ten patients were excluded. Proportions were pooled using random-effects models.
RESULTS RESULTS
We identified 18 studies from 7 countries; all were case reports and case series from autopsies. All the patients were over 15 years old, and 67.2% were male. We performed a meta-analysis of 5 studies, including 116 patients. Pooled prevalence estimates of liver histopathological findings were hepatic steatosis 55.1% [95% confidence interval (CI): 46.2-63.8], congestion of hepatic sinuses 34.7% (95%CI: 7.9-68.4), vascular thrombosis 29.4% (95%CI: 0.4-87.2), fibrosis 20.5% (95%CI: 0.6-57.9), Kupffer cell hyperplasia 13.5% (95%CI: 0.6-54.3), portal inflammation 13.2% (95%CI: 0.1-48.8), and lobular inflammation 11.6% (95%CI: 0.3-35.7). We also identified the presence of venous outflow obstruction, phlebosclerosis of the portal vein, herniated portal vein, periportal abnormal vessels, hemophagocytosis, and necrosis.
CONCLUSION CONCLUSIONS
We found a high prevalence of hepatic steatosis and vascular thrombosis as major histological liver features. Other frequent findings included portal and lobular inflammation and Kupffer cell hyperplasia or proliferation. Further studies are needed to establish the mechanisms and implications of these findings.

Identifiants

pubmed: 33505145
doi: 10.3748/wjg.v26.i48.7693
pmc: PMC7789052
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

7693-7706

Informations de copyright

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: The authors have nothing to disclose.

Références

Lancet. 2020 Aug 1;396(10247):320-332
pubmed: 32682491
J Hepatol. 2020 Oct;73(4):807-816
pubmed: 32437830
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417
pubmed: 32172546
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
Hepatology. 2004 Feb;39(2):302-10
pubmed: 14767982
Am J Clin Pathol. 2020 Sep 8;154(4):466-474
pubmed: 32681166
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):97-99
pubmed: 32075364
Aliment Pharmacol Ther. 2020 Aug;52(4):584-599
pubmed: 32638436
Hepatology. 2020 May 16;:
pubmed: 32415860
Mod Pathol. 2020 Jun;33(6):1007-1014
pubmed: 32291399
Am J Clin Pathol. 2020 May 5;153(6):725-733
pubmed: 32275742
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Emerg Infect Dis. 2020 Sep;26(9):2005-2015
pubmed: 32437316
Fetal Pediatr Pathol. 2020 Jun;39(3):263-268
pubmed: 32401577
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Liver Int. 2020 Sep;40(9):2095-2103
pubmed: 32239796
Liver Int. 2020 May;40(5):998-1004
pubmed: 32170806
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
J Hepatol. 2020 Sep;73(3):719-721
pubmed: 32348790
Ann Intern Med. 2020 Sep 1;173(5):350-361
pubmed: 32422076
Emerg Infect Dis. 2020 Sep;26(9):
pubmed: 32412897
Histopathology. 2020 Aug;77(2):198-209
pubmed: 32364264
Am J Pathol. 2016 Mar;186(3):652-8
pubmed: 26857507
Crit Care. 2020 Aug 12;24(1):495
pubmed: 32787909
Hepatology. 2020 Aug;72(2):389-398
pubmed: 32359177
Liver Int. 2020 Oct;40(10):2568
pubmed: 32306495
Arch Pathol Lab Med. 2020 Apr 17;:
pubmed: 32302212
Gastroenterology. 2020 Aug;159(2):768-771.e3
pubmed: 32376408
Gastroenterology. 2020 Jul;159(1):81-95
pubmed: 32251668
Liver Int. 2020 Sep;40(9):2110-2116
pubmed: 32654359
JAMA. 2020 Jun 23;323(24):2518-2520
pubmed: 32437497
J Hepatol. 2020 Sep;73(3):566-574
pubmed: 32298767
Cardiovasc Pathol. 2020 Sep - Oct;48:107233
pubmed: 32434133
Gastroenterology. 2020 Sep;159(3):1148-1150
pubmed: 32437750
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2384-2385
pubmed: 32425706
Sci Rep. 2017 Aug 22;7(1):9110
pubmed: 28831119
Zhonghua Bing Li Xue Za Zhi. 2003 Jun;32(3):201-4
pubmed: 12882681
Clin Gastroenterol Hepatol. 2020 Jun;18(7):1561-1566
pubmed: 32283325
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Int J Mol Sci. 2020 May 17;21(10):
pubmed: 32429572
Gastroenterology. 2020 Jul;159(1):320-334.e27
pubmed: 32407808
Am J Forensic Med Pathol. 2020 Sep;41(3):143-151
pubmed: 32379077
Ann Hepatol. 2020 Jul - Aug;19(4):353-358
pubmed: 32425991
Thromb Res. 2020 Jun;190:62
pubmed: 32305740
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288

Auteurs

Luis Antonio Díaz (LA)

Department of Gastroenterology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile.

Francisco Idalsoaga (F)

Department of Internal Medicine, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile.

Macarena Cannistra (M)

School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile.

Roberto Candia (R)

Department of Gastroenterology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile.

Daniel Cabrera (D)

Facultad de Ciencias Médicas, Universidad Bernardo O'Higgins, Santiago 8320000, Chile.

Francisco Barrera (F)

Department of Gastroenterology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile.

Alejandro Soza (A)

Department of Gastroenterology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile.

Rondell Graham (R)

Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Minnesota, MN 55902, United States.

Arnoldo Riquelme (A)

Department of Gastroenterology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile.

Marco Arrese (M)

Department of Gastroenterology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile.

Michael D Leise (MD)

Division of Gastroenterology and Hepatology, Mayo Clinic Rochester, Minnesota, MN 55905, United States.

Juan Pablo Arab (JP)

Department of Gastroenterology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 8320000, Chile. jparab@med.puc.cl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH